Skip to main content

Table 3 Ongoing phase III immunotherapy trials in mCRPC

From: The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

Trial

National clinical trial identifier

Status*

PSA-TRICOM +/- GM-CSF

NCT01322490

Ongoing, Expected completion date June 2017

Tasquinimod

NCT01234311

Completed, Reported in 2016 [61]

Ipilimumab in chemo-naïve mCRPC

NCT01057810

Completed, Reported in 2016 [38]

  1. * As determined by ClinicalTrials.gov accessed October 31, 2016
Back to article page